Rosuvastatin Combined with Silibinin Capsule in Treatment for Hyperlipidemic Patients with Nonalcoholic Fatty Liver Disease: a Randomized Double-Blind Controlled Study
Liu Binghua,Dong Fuqiang,Jiang Yong,Zhang Lijuan,Zhang Zhiguang
DOI: https://doi.org/10.3760/cma.j.issn.1671-7368.2019.06.006
2019-01-01
Abstract:Objective To investigate the efficacy of rosuvastatin combined with silibinin capsule in treatment of hyperlipidemic patients with nonalcoholic fatty liver disease.Methods One hundred and nineteen hyperlipidemic patients with non-alcoholic fatty liver disease admitted in hospital from January 2016 to March 2017 were randomly assigned into two groups:60 patients received rosuvastatin(10 mg,q.d) and silibinin capsules(70 mg,t.i.d.,study group) and 59 patients received starch tablets(10 mg,q.d) and silibinin capsules(70 mg,t.i.d.,control group).The blood lipid,liver function,inflammatory factors,liver CT value,the specific CT value of liver and spleen were compared at baseline and 6 months after intervention.Results Compared to baseline values,the levels of total cholesterol (TC),triglyceride (TG),alanine aminotransferase (ALT),γ-glutamyltranspeptidase (GGT),TNF-α,IL-6,and CRP were decreased (t=2.44,2.04,2.48,6.95,2.38,2.78,3.97,all P＜0.05);and the levels of HDL-C,liver CT value,liver/spleen CT value ratio were increased (t=5.44,2.26,2.08,all P＜0.05) after treatment in study group.The improvement of TG,LDL-C,ALT,GGT,TNF-α,CRP,liver CT value,liver/spleen CT value ratio were more marked than those of the control group (P＜0.05) (t=1.92,2.65,2.02,5.62,2.11,2.20,2.22,2.08,all P＜0.05).The effective rate of study group was higher than that of the control group[98.2％(55/56) vs.85.7％(48/56),x2=2.05,P=0.04];the adverse reactions were similar in two groups.Conclusion Compared with silibinin alone,rosuvastatin combined with silibinin capsules is more effective in treatment of hyperlipidemic patients with nonalcoholic fatty liver disease,which can significantly improve the blood lipids,liver function,inflammatory response and aliphatic degree without increase of adverse reaction.